Xywav And Epidiolex Will Expand CNS And Orphan Markets
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 17 Analysts
Published
23 Apr 25
Updated
20 Aug 25
AnalystHighTarget's Fair Value
US$230.00
46.5% undervalued intrinsic discount20 Aug
US$123.11
1Y
8.1%7D
4.5%